for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Becton Dickinson and Co

BDX.N

Latest Trade

258.59USD

Change

1.79(+0.70%)

Volume

401,525

Today's Range

255.74

 - 

259.12

52 Week Range

208.67

 - 

264.72

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
256.80
Open
256.66
Volume
401,525
3M AVG Volume
21.36
Today's High
259.12
Today's Low
255.74
52 Week High
264.72
52 Week Low
208.67
Shares Out (MIL)
269.95
Market Cap (MIL)
69,807.44
Forward P/E
22.14
Dividend (Yield %)
1.19

Next Event

Q4 2019 Becton Dickinson and Co Earnings Call

Latest Developments

More

BD Says Thomas E. Polen Appointed Chief Executive Officer

Becton Dickinson Announces Q3 Earnings Per Share $1.51

Becton Dickinson And Co Sets Quarterly Dividend Of $0.77 Per Share

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Becton Dickinson and Co

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.

Industry

Medical Equipment & Supplies

Contact Info

1 Becton Dr

+1.201.8476800

http://www.bd.com/

Executive Leadership

Vincent A. Forlenza

Chairman of the Board, Chief Executive Officer

Thomas E. Polen

President, Chief Operating Officer

Christopher R. Reidy

Chief Financial Officer, Executive Vice President, Chief Administrative Officer

Betty D. Larson

Executive Vice President- Human Resources, Chief Human Resources

Samrat S. Khichi

Executive Vice President, General Counsel

Key Stats

1.82 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

12.5K

2017

12.1K

2018

16.0K

2019(E)

17.3K
EPS (USD)

2016

8.590

2017

9.480

2018

11.010

2019(E)

11.681
Price To Earnings (TTM)
64.58
Price To Sales (TTM)
4.08
Price To Book (MRQ)
3.25
Price To Cash Flow (TTM)
20.78
Total Debt To Equity (MRQ)
93.89
LT Debt To Equity (MRQ)
83.81
Return on Investment (TTM)
2.65
Return on Equity (TTM)
2.35

Latest News

Latest News

U.S. investigates bloodstream infections for link to heparin syringes

Health agencies are investigating an outbreak of bloodstream infections in children from four U.S. states that may be linked to heparin and saline syringes made by Becton Dickinson and Co, the agencies told Reuters. The U.S. Centers for Disease Control and Prevention has...

BRIEF-Becton Dickinson Reports Q2 Loss Per Share $0.19

* BD ANNOUNCES RESULTS FOR 2018 SECOND FISCAL QUARTER; RAISES FISCAL 2018 GUIDANCE

BRIEF-Becton Dickinson Files For Potential Mixed Shelf Offering

* BECTON DICKINSON AND CO FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING Source text (https://bit.ly/2HvryvV) Further company coverage:

BRIEF-Becton Dickinson Updates Instructions for Use for Certain BD Vacutainer Blood Collection Tubes

* BECAME AWARE OF CONCERNS ABOUT INACCURATE LEAD TEST RESULTS FROM MAGELLAN DIAGNOSTICS LEADCARE TESTING SYSTEMS

BRIEF-Becton, Dickinson To Divest Remaining Investment In Vyaire Medical

* BD TO DIVEST REMAINING INVESTMENT IN VYAIRE MEDICAL TO FUNDS MANAGED BY APAX PARTNERS

BRIEF-Becton Dickinson Launches Circulating Cell-Free DNA Blood Collection Tube in Western Europe

* BD LAUNCHES CIRCULATING CELL-FREE DNA BLOOD COLLECTION TUBE FOR CANCER AND NON-INVASIVE PRENATAL TESTING APPLICATIONS

BRIEF-Becton Dickinson Files For Offering EUR 300 Mln Add. 0.368% Notes

* BECTON DICKINSON AND CO FILES FOR OFFERING EUR 300 MILLION AGGREGATE PRINCIPAL AMOUNT OF ADDITIONAL 0.368% NOTES DUE 2019 - SEC FILING

BRIEF-Becton Dickinson Says Received Pre-Market Approval From FDA For BD Onclarity HPV Assay

* FDA APPROVES NEW HPV TEST THAT DETECTS AND IDENTIFIES HPV GENOTYPES THAT PUT WOMEN AT HIGH RISK FOR CERVICAL CANCER Source text for Eikon: Further company coverage:

BRIEF-Becton Dickinson Q1 Loss Per Share $0.76

* BD ANNOUNCES RESULTS FOR 2018 FIRST FISCAL QUARTER; PROVIDES FISCAL 2018 GUIDANCE UPDATED FOR INCLUSION OF BARD

BRIEF-BD Statement On FDA Warning Letter For Preanalytical Systems Business Unit

* BD STATEMENT ON FDA WARNING LETTER FOR PREANALYTICAL SYSTEMS BUSINESS UNIT

BRIEF-FDA Issues Warning Letter To Becton Dickinson & Co

* FDA WARNS BECTON DICKINSON & COMPANY OF SIGNIFICANT VIOLATIONS OF THE LAW AS PART OF ONGOING INVESTIGATION INTO LEAD TESTING ISSUES

UPDATE 1-Becton Dickinson's $24 bln takeover of C R Bard set to close after China nod

* Becton had said China approval was last hurdle for deal to close

China commerce ministry conditionally approves Becton Dickinson-C R Bard merger

China's commerce ministry said on Thursday that it has conditionally approved a merger between U.S. medical equipment supplier Becton Dickinson <BDX.N> and its U.S. peer C R Bard <BCR.N>.

Becton, Dickinson to divest two product lines for C R Bard buy: FTC

U.S. medical equipment supplier Becton Dickinson <BDX.N> and C R Bard <BCR.N> have agreed to divest two product lines to satisfy U.S. Federal Trade Commission concerns their proposed $24 billion merger would negatively affect competition.

BRIEF-BD Issues Statement On FTC Clearance Of Bard Acquisition

* EXPECT BARD DEAL WILL CLOSE IN DECEMBER, PENDING APPROVAL BY CHINA MINISTRY OF COMMERCE, SOME OTHER CONDITIONS Source text for Eikon: Further company coverage:

Becton, Dickinson agrees to divest two product lines for C R Bard buy -FTC

U.S. medical equipment supplier Becton Dickinson and C R Bard have agreed to divest two product lines to settle U.S. Federal Trade Commission charges that Becton, Dickinson's proposed $24 billion acquisition of Bard would negatively impact competition in those markets, the...

BRIEF-Becton Dickinson And Co Says CEO Vincent Forlenza's FY 2017 Total Compensation Was $13.1 Mln

* BECTON DICKINSON AND CO SAYS CHAIRMAN AND CEO VINCENT FORLENZA'S FY 2017 TOTAL COMPENSATION WAS $13.1 MILLION VERSUS $13.9 MILLION IN FY 2016 - SEC FILING Source text: (http://bit.ly/2ktIxQL) Further company coverage:

BRIEF-BD board increases dividend

* Becton Dickinson And Co - declared a quarterly dividend of $0.75 per common share, an increase of 2.7 percent from previous quarter Source text for Eikon: Further company coverage:

BRIEF-Merit Medical signs purchase agreement with BD for divestment assets

* Merit Medical signs purchase agreement with BD for divestment assets

BRIEF-Becton Dickinson says Q4 earnings per share $1.24

* BD announces results for 2017 fourth fiscal quarter and full year; provides fiscal 2018 guidance

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up